Texas Sues Meta Over WhatsApp Encryption Claims 
Walmart Stock Falls Despite Strong Q1 Revenue Beat and E-Commerce Growth 
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal 
Google Expands AI Partnership With Singapore Government 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Goldman Sachs to Pay $500M in 1MDB Shareholder Fraud Settlement 
Intuit Raises Full-Year Forecast After Strong Q3 Earnings Despite Stock Drop 
Nvidia Beats Earnings Expectations as AI Demand Drives Record Growth 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
SpaceX Eyes AI Computing Expansion Ahead of Historic IPO 
JPMorgan Sees Large-Cap Biotech Stocks Entering New Growth Phase in 2026 
OpenAI Eyes IPO Filing as Early as This Week Amid Rising AI Competition 
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
